Novel proteasome inhibitors to overcome bortezomib resistance

Journal of the National Cancer Institute

Volumn 103, Issue 13, 2011, Pages 1007-1017

  Ruschak, Amy M ^a   Slassi, Malik ^b   Kay, Lewis E ^a   Schimmer, Aaron D ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Fluorinov Pharma   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 8 HYDROXYQUINOLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARFILZOMIB; CEP 18770; CHLOROQUINE; CLIOQUINOL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LACTACYSTIN BETA LACTONE; LENALIDOMIDE; MELPHALAN; MLN 2238; MLN 9708; ONX 0912; PR 39; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; QUINOLINE; SALINOSPORAMIDE A; THALIDOMIDE; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG STABILITY; DRUG TOLERABILITY; ENZYME STRUCTURE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; INTESTINE INFECTION; LEUKEMIA; LOW DRUG DOSE; MANTLE CELL LYMPHOMA; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PARASITOSIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ALLOSTERIC SITE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CHLOROQUINE; CLIOQUINOL; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROXYQUINOLINES; LACTONES; NEOPLASMS; OLIGOPEPTIDES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; PYRROLES; THREONINE; UBIQUITINATED PROTEINS; UBIQUITINATION;

EID: 79960208716     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr160     Document Type: Review

References (95)

1. Walden H, Podgorski MS, Huang DT, et al. The structure of the APPBP1-UBA3-NEDD8-ATP complex reveals the basis for selective ubiquitin-like protein activation by an E1. Mol Cell. 2003;12(6):1427-1437. (Pubitemid 38037012)
2. Walden H, Podgorski MS, Schulman BA. Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8. Nature. 2003;422(6929):330-334. (Pubitemid 36378362)
3. Lois LM, Lima CD. Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. Embo J. 2005;24(3):439-451. (Pubitemid 40343247)
4. Hershko A, Heller H, Elias S, Ciechanover A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem. 1983;258(13):8206-8214.
5. Chau V, Tobias J, Bachmair A, et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science. 1989;243(4898):1576-1583. (Pubitemid 19090506)
6. Jin J, Li X, Gygi SP, Harper JW. Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature. 2007;447(7148):1135-1138. (Pubitemid 47014428)
7. Haas AL, Bright PM. The resolution and characterization of putative ubiquitin carrier protein isozymes from rabbit reticulocytes. J Biol Chem. 1988;263(26):13258-13267.
8. Kraft E, Stone SL, Ma L, et al. Genome analysis and functional characterization of the E2 and RING-type E3 ligase ubiquitination enzymes of Arabidopsis. Plant Physiol. 2005;139(4):1597-1611. (Pubitemid 43899804)
9. Terrell J, Shih S, Dunn R, Hicke L. A function for monoubiquitination in the internalization of a G protein-coupled receptor. Mol Cell. 1998;1(2):193-202. (Pubitemid 128378660)
10. Polo S, Sigismund S, Faretta M, et al. A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature. 2002;416(6879):451-455. (Pubitemid 34272882)
11. Zhou W, Zhu P, Wang J, et al. Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation. Mol Cell. 2008;29(1):69-80.
12. Nijman SM, Huang TT, Dirac AM, et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell. 2005;17(3):331-339. (Pubitemid 40193305)
13. Huang TT, D'Andrea AD. Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol. 2006;7(5):323-334.
14. Huang TT, Nijman SM, Mirchandani KD, et al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol. 2006;8(4):339-347.
15. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65(65):801-847. (Pubitemid 26255262)
16. Baumeister W, Walz J, Zuhk F, Seemuller E. The proteasome: paradigm of a self-compartmentalization protease. Cell. 1998;92(6):367-380.
17. Glickman MH, Rubin DM, Coux O, et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell. 1998;94(5):615-623. (Pubitemid 28427580)
18. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science. 1995;268(5210):533-539.
19. Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature. 1997;386(6624):463-471. (Pubitemid 27164066)
20. Groll M, Bajorek M, Kohler A, et al. A gated channel into the proteasome core particle. Nat Struct Biol. 2000;7(11):1062-1067.
21. Bedford L, Paine S, Sheppard PW, Mayer RJ, Roelofs J. Assembly, structure, and function of the 26S proteasome. Trends Cell Biol. 2010;20(7):391-401.
22. Unno M, Mizushima T, Morimoto Y, et al. The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure. 2002;10(5):609-618. (Pubitemid 34518706)
23. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem. 1997;272(40):25200-25209. (Pubitemid 27415707)
24. Chen P, Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell. 1996;86(6):961-972. (Pubitemid 26336800)
25. Ditzel L, Huber R, Mann K, Heinemeyer W, Wolf DH, Groll M. Conformational constraints for protein self-cleavage in the proteasome. J Mol Biol. 1998;279(5):1187-1191. (Pubitemid 28302394)
26. Nussbaum AK, Dick TP, Keilholz W, et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci USA. 1998;95(21):12504-12509.
27. Dick TP, Nussbaum AK, Deeg M, et al. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem. 1998;273(40):25637-25646. (Pubitemid 28475784)
28. Arendt CS, Hochstrasser M. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc Natl Acad Sci USA. 1997;94(14):7156-7161. (Pubitemid 27345284)
29. Stadtmueller BM, Hill CP. Proteasome activators. Mol Cell. 2011;41(1):8-19.
30. Yu Y, Smith DM, Kim HM, Rodriguez V, Goldberg AL, Cheng Y. Interactions of PAN's C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome-ATPase interactions. Embo J. 2010;29(3):692-702.
31. Kisselev AF, Akopian TN, Goldberg AL. Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes. J Biol Chem. 1998;273(4):1982-1989. (Pubitemid 28069243)
32. Akopian TN, Kisselev AF, Goldberg AL. Processive degradation of proteins and other catalytic properties of the proteasome from Thermoplasma acidophilum. J Biol Chem. 1997;272(3):1791-1798. (Pubitemid 27043269)
33. Groll M, Heinemeyer W, Jager S, et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci USA. 1999;96(20):10976-10983. (Pubitemid 29487315)
34. Brannigan JA, Dodson G, Duggleby HJ, et al. A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature. 1995;378(6555):416-419.
35. Glynne R, Powis SH, Beck S, Kelly A, Kerr LA, Trowsdale J. A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature. 1991;353(6342):357-360. (Pubitemid 21912511)
36. Martinez CK, Monaco JJ. Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene. Nature. 1991;353(6345):664-667. (Pubitemid 21912585)
37. Nandi D, Jiang H, Monaco JJ. Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol. 1996;156(7):2361-2364. (Pubitemid 26091557)
38. Altun M, Galardy PJ, Shringarpure R, et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 2005;65(17):7896-7901. (Pubitemid 41297267)
39. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009;113(19):4667-4676.
40. Busse A, Kraus M, Na IK, et al. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer. 2008;112(3):659-670. (Pubitemid 351186207)
41. Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009;114(16):3439-3447.
42. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609- 2617. (Pubitemid 36741588)
43. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867-4874. (Pubitemid 46655613)
44. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67(4):1783-1792. (Pubitemid 46383406)
45. Bazzaro M, Lee MK, Zoso A, et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 2006;66(7):3754-3763.
46. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-3076. (Pubitemid 32691956)
47. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8(5):407-419. (Pubitemid 41579835)
48. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006;14(3):451-456. (Pubitemid 43363478)
49. Groll M, Huber R, Potts BC. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc. 2006;128(15):5136-5141.
50. Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev. 2007;107(3):687-717. (Pubitemid 46502369)
51. Williamson MJ, Blank JL, Bruzzese FJ, et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther. 2006;5(12):3052-3061. (Pubitemid 46092046)
52. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5(5):417-421. (Pubitemid 38610244)
53. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487- 2498. (Pubitemid 41007864)
54. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
55. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-686.
56. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101-5109.
57. Kumar SK, Flinn I, Noga SJ, et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010;24(7):1350-1356.
58. Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004;10(10):3371-3376. (Pubitemid 38685442)
59. Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, Greipp PR. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia. 2010;24(8):1406-1411.
60. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112(6):2489-2499.
61. Lu S, Yang J, Chen Z, et al. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp Hematol. 2009;37(7):831-837.
62. Li X, Wood TE, Sprangers R, et al. Effect of noncompetitive proteasome inhibition on bortezomib resistance. J Natl Cancer Inst. 2010;102(14):1069-1082.
63. Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, Rahemtulla A. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk Res. 2006;30(2):240-241. (Pubitemid 41773346)
64. Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR. Characterization of bortezomib-adapted I-45 mesothelioma cells. Mol Cancer. 2010;9:110.
65. Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003;63(19):6174-6177. (Pubitemid 37255160)
66. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70(5):1970- 1980.
67. Sanchez E, Li M, Steinberg JA, et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol. 2010;148(4):569-581.
68. Piva R, Ruggeri B, Williams M, et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008;111(5):2765-2775.
69. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281-3290. (Pubitemid 350106321)
70. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383-6391. (Pubitemid 47037522)
71. O'Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009;15(22):7085-7091.
72. Martin T, Wang M, Vij R, et al. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Orlando, FL: American Society of Hematology; 2010. Abstract 985.
73. Zhou HJ, Aujay MA, Bennett MK, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem. 2009;52(9):3028-3038.
74. Chauhan D, Singh AV, Aujay M, et al. A novel orally active proteasome inhibitor ONX 0912 trigger in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010;116(23):4906-4915.
75. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl. 2003;42(3):355-357. (Pubitemid 36176323)
76. Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol. 2010;149(4):550-559.
77. Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 2007;110(1):267-277. (Pubitemid 47026844)
78. Richardson P, Hofmeister C, Zimmerman T, et al. Phase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myeloma. In: Orlando, FL: American Society of Hematology Annual Meeting; 2010. Abstract 2770.
79. Gudmundsson GH, Magnusson KP, Chowdhary BP, Johansson M, Andersson L, Boman HG. Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL-39. Proc Natl Acad Sci USA. 1995;92(15):7085-7089.
80. Li J, Post M, Volk R, et al. PR39, a peptide regulator of angiogenesis. Nat Med. 2000;6(1):49-55. (Pubitemid 30048525)
81. Gaczynska M, Osmulski PA, Gao Y, Post MJ, Simons M. Proline-and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry. 2003;42(29):8663-8670. (Pubitemid 36899808)
82. Sprangers R, Li X, Mao X, Rubinstein JL, Schimmer AD, Kay LE. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. Biochemistry. 2008;47(26):6727-6734. (Pubitemid 351898927)
83. Richards DA. Prophylactic value of clioquinol against travellers' diarrhoea. Lancet. 1971;1(7688):44-45.
84. Woodward WE, Rahman AS. Trial of clioquinol in cholera. Lancet. 1969;2(7614):270.
85. Nakae K, Yamamoto S, Shigematsu I, Kono R. Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey. Lancet. 1973;1(7796):171-173.
86. Konagaya M, Matsumoto A, Takase S, et al. Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban. J Neurol Sci. 2004;218(1-2):85-90. (Pubitemid 38169399)
87. Mao X, Li X, Sprangers R, et al. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia. 2009;23(3):585-590.
88. Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol. Cancer Res. 2005;65(8):3389-3395. (Pubitemid 40524624)
89. Chen D, Cui QC, Yang H, et al. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res. 2007;67(4):1636-1644. (Pubitemid 46383389)
90. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res. 2005;7(6):R897-R908.
91. Ding WQ, Lind SE. Metal ionophores-an emerging class of anticancer drugs. IUBMB Life. 2009;61(11):1013-1018.
92. Geraki K, Farquharson MJ, Bradley DA. Concentrations of Fe, Cu and Zn in breast tissue: a synchrotron XRF study. Phys Med Biol. 2002;47(13):2327-2339. (Pubitemid 34812209)
93. Diez M, Cerdan FJ, Arroyo M, Balibrea JL. Use of the copper/zinc ratio in the diagnosis of lung cancer. Cancer. 1989;63(4):726-730. (Pubitemid 19050277)
94. Yoshida D, Ikeda Y, Nakazawa S. Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumors. J Neurooncol. 1993;16(2):109-115. (Pubitemid 23304718)
95. Xu GW, Ali M, Wood TE, et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood. 2010;115(11):2251-2259.